Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?

Pneumococcal Vaccine Filing In H2

 
• By Vibha Ravi

Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.

Clinical Research Image
Aurobindo Is Making Progress In Biosimilars' Development • Source: Shutterstock

More from Strategy

More from Business